Drug Profile
Anagrelide controlled release - AOP Orphan Pharmaceuticals
Alternative Names: Anagrelide AOP; Anagrelide CR; Anagrelide retard -AOP Orphan Pharmaceuticals; ANAT2; AnathrombLatest Information Update: 20 Apr 2022
Price :
$50
*
At a glance
- Originator AOP Orphan Pharmaceuticals AG
- Class 3-ring heterocyclic compounds; Antiplatelets; Antithrombotics; Imidazoles; Quinazolines; Small molecules
- Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Essential thrombocythaemia
Most Recent Events
- 20 Apr 2022 Discontinued - Phase-III for Essential thrombocythaemia in Russia (PO)
- 20 Apr 2022 Discontinued - Phase-III for Essential thrombocythaemia in Ukraine (PO)
- 20 Apr 2022 No development reported - Preregistration for Essential thrombocythaemia in European Union (PO)